A comparison of the efficacy and safety of 0.025% and 0.05% tretinoin cream in the treatment of acanthosis nigricans

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201124001

Enrollment

Registered

2020-11-24

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acanthosis nigricans Acanthosis nigricans&#44

Interventions

Active Comparator Drug,Active Comparator Drug

0.025% tretinoin cream ,0.05% tretinoin cream

To assess the efficacy and safety of 0.025% tretinoin cream ,To assess the efficacy and safety of 0.05% tretinoin cream

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The participants aged over 18 years with a diagnosis of acanthosis nigricans

Exclusion criteria

Exclusion criteria: - Vulnerable skin diseases - Infectious skin diseases - Other recent diseases involving the neck - Other serious medical disorders e.g. DM, liver disease - Any patients having received other therapies for up to 4 weeks prior to enrollment, such as corticosteroids, vitamin D, trichloroacetic acid (TCA), or other chemical peeling agents. - Photosensitive skin - Immunocompromised host - Pregnancy and lactation - Receiving oral retinoids - Neck tattoo

Design outcomes

Primary

Measure	Time frame
the efficacy week 0, 2, 4 and week 8 the Mexameter MX18	—

Secondary

Measure	Time frame
The efficacy week 0,2,4,8 using the investigatorâ€™s global evaluation (IGE) ,Side effect week 0,2,4,8 cutaneous irritation grading scales	—

Countries

Thailand

Contacts

Public ContactChawan Kritsanaviparkporn

Faculty of Medicine, Srinakharinwirot University

c.kritsanaviparkporn@gmail.com0854870548

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026